What generation of targeted drug is Ensartinib?

Ensartinib is a second-generation targeted drug for anaplastic lymphoma kinase (ALK). It is mainly indicated for the treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). By inhibiting the kinase activity of ALK protein and blocking the growth signals of tumor cells, it has stronger target selectivity and the ability to cover some drug-resistant mutations.